Shares of Biocytogen-B (02315) have risen by more than 6%. At the time of writing, the stock is up 4.11% to HK$40.5, with a turnover of approximately HK$48.83 million.
A recent research report highlights the ongoing expansion of China's preclinical CRO market, which reached RMB 40.58 billion in 2023 and is projected to grow to RMB 89.93 billion by 2030. The genetically engineered mouse model sector remains highly active, with competition shifting towards comprehensive capabilities including model variety and breeding efficiency.
Analysts note that Biocytogen-B's model animal and preclinical CRO businesses have maintained robust growth for several years. The company has established deep, strategic partnerships with leading global innovative pharmaceutical firms. Its strong competitive moats, combined with favorable industry tailwinds, are expected to support continued market share gains.
Business Progress and Platform Development
On the operational front, leveraging its RenMice fully human antibody platform and the "Thousand Mice Ten Thousand Antibodies" project, the company had completed evaluation and research on approximately 1,200 targets by December 31, 2025, with antibody development initiated for nearly all of them. This effort has generated a library of over one million antibody sequences with diverse binding epitopes.
The antibody business achieved a compound annual growth rate of 37.8% from 2022 to 2025, with gross margins consistently above 85%. In May 2026, the company launched its next-generation AI platform, RenSuper, which introduces intelligent and automated antibody screening, leading to significant efficiency improvements.
Future Growth Outlook
The integration of AI technology, coupled with its licensing and high-margin commercialization strategy, is seen as continuously unlocking the platform's value. This positions the company with outstanding growth potential as its platform business accelerates.
Comments